First multicenter study submitted and approved through CTIS

The EU-SolidAct study, the purpose of which is to evaluate the safety and effectiveness of therapeutic substances in hospitalized patients diagnosed with COVID 19 through a platform design, is being implemented in the Czech Republic in cooperation with the CZECRIN research infrastructure. It is the first multicenter study that was submitted and approved through the new European CTIS portal (you can find more information about the portal in our post from 25/05/2022).

You can read the reason why the sponsor decided to present the study in a new way, the advantages and experiences from the portal in an interview with Inge Christoffer Olsne, representative of the sponsor Oslo University Hospital, in the July newsletter of the European Medicines Agency.